Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Dermatology"
DOI: 10.1111/bjd.16890
Abstract: Adalimumab is used to treat several inflammatory diseases, including plaque psoriasis. GP2017 is a proposed adalimumab biosimilar. read more here.
Keywords: randomized study; iii randomized; phase iii; proposed adalimumab ... See more keywords